Review
Copyright ©The Author(s) 2022.
World J Methodol. Sep 20, 2022; 12(5): 331-349
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.331
Table 1 The various hematological parameters in significant relation to coronavirus disease 2019 and their mechanisms
Hematological parameter
Significant relation to COVID-19
Mechanism
High RDW (greater than 14.5%) Increase in mortality risk (from 11% to 31%)[86]Not completely understood however reports suggested elevated RDW was attributed to affection of RBC production kinetics[86]
Leucopenia or lymphopenia (ALC < 1.0 × 109/L)Observed in most of COVID cases especially hospitalized patients and associated with poor prognosis[86](1) Defective immune response; and (2) Drug induced as with steroids[87]
Normal or increased platelet count Found in some cases of COVID-19May be caused by to the large amounts of platelets produced in response to increased thrombopoietin formation from liver stimulation and megakaryocytes in the lung[88]
Prolonged PT and aPTT, elevations of D dimer, fibrinogen and FDP and decreased levels of antithrombin IIIDirect relationship was observed between severity of COVID and affection of coagulation profile, Overt DIC (ISTH score of 5 and higher) is seen more frequently in non-survivors[89]aPTT prolongation is caused by increased Factor VIII level and Factor XII deficiency secondary to the presence of factor XII inhibitors. Von Willebrand factor is quantitatively increased. LA is positive in 91% of those with prolonged aPTT. The presence of both LA and Factor XII deficiency are not associated with bleeding tendency
Table 2 Various laboratory parameters that are altered in severe acute respiratory syndrome coronavirus 2 and their implications in coronavirus disease 2019 severity
Clinical index
Alterations with COVID-19 severity
Ref.
Neutrophil-to-lymphocyte ratioIncreased[84,122-124,131,134-136]
CRPIncreased[122,124,125,128,129,131,134-136,137-144]
PlateletsDecreased[78,83,122,126,129,131-133,136,145,146]
LymphocytesDecreased[78,128,129,131,134-136,147,148]
D-dimerIncreased[55,83,84,127,128,131,137,144-146,149-152]
Ferritin Increased[91,94,128,129,131,134,135,137-139,144,153-155]
ProcalcitoninIncreased[83,84,128,144,156-158]
Lactate dehydrogenaseIncreased[106,129-131,152,159-173]
Albumin Decreased[111,116,128,129,136,148,174-186]
Table 3 Frequency of venous thromboembolic complications in coronavirus disease 2019 patients
Ref.
Proportion
Cumulative incidence
Median follow-up
Patients
Cui et al[59]20/81 (25%)NRNRICU patients
Klok et al[60]68/184 (37%)57% or 49% adjusted for competing risk of death14 dICU patients only.19 PE were limited to subsegmental arteries.65/68 venous events were PE (95.6%)
Poissy et al[61]VTE 22.2% of 54 ICU admitted
Helms et al[44]27/150 (18%)NRNRICU patients with ARDS 25/27 events were PE (92.5%)
Poissy et al[61]PE only 22/107 (20.6%)20.4% calculated at ICU day 156 dICU only
Middeldorp et al[63]Venous thromboembolism 39% of COVID-19 ICU cases 74 patients
Llitjos et al[64]DVT: 18/26 (69%); PE: 6/26 (23%)NRNRICU patients. Systematic ultrasound screening
Léonard-Lorant et al[183]PE only 32/106 (30%)NRNR24/32 (75%) PE-positive patients were in the ICU
Grillet et al[184]PE only 23/100 (23%)NRNRWard: 6/61 (9.8%); ICU: 17/39 (43.6%)
Middeldorp et al[63]33/198 (17%)15% at 7 d; 34% at 14 d5 dWard: 4/123 (3.3%); ICU: 35/75 (47%); 11 (5.4%) clots detected on screening 11/33 events were PE (33%)
Lodigiani et al[185]16/362 (4.4%)21% (time not reported)10 dICU 4/48(8.3%); Ward 12/314 (3.8%)
Thomas et al[186]6/63 (9%)27%8 dICU patients
Cattaneo et al[108]DVT only 0/388 (0%)NRNRNon-ICU Ward 64 patients had screening ultrasound. All negative